Will a biotech rival finally shake up AbbVie's $2B Botox cosmetic franchise? Revance will find out soon

Amber Tong

For 20 years, Botox — short for the neurotoxic protein botulinum toxin — has reigned supreme as the most popular cosmetic procedure. Even as Evolus managed to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Will a biotech rival finally shake up AbbVie's $2B Botox cosmetic franchise? Revance will find out soon

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Rare disease biopharma companies weigh in on FDA's new innovation hub

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Will a biotech ri­val fi­nal­ly shake up Ab­b­Vie's $2B Botox cos­met­ic fran­chise? Re­vance will find out soon

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Will a biotech rival finally shake up AbbVie's $2B Botox cosmetic franchise? Revance will find out soon